

Express Mail Label No.: EV05 00732US
 Date of Deposit: August 28, 2002

Attorney Docket No. 21402-042 (CURA-342)



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Rastelli, et al

SERIAL NUMBER: 10/016,253

EXAMINER: Not Yet Assigned

FILING DATE: December 10, 2001

ART UNIT: 1614

FOR: METHODS OF DETECTING AND TREATING TUBEROUS SCLEROSIS
 COMPLEX ASSOCIATED DISORDERS

U. S. Patent and Trademark Office
 BOX SEQUENCE
 P. O. Box 2327
 Arlington, VA 22202



30623

PATENT TRADEMARK OFFICE

TRANSMITTAL LETTER

Enclosed herewith are the following for the above-identified non-provisional patent application:

1. Petition for Extension of Time (1 pg)
2. Copy of Notice to File Missing Parts (2 pgs);
3. Check No. 13868 in the amount of \$130.00 to cover the Surcharge;
4. Preliminary Amendment and Response to Notice to File Missing Parts (2 pgs);
5. Copy of Combined Declaration and Power of Attorney (3 counterparts) (9 pgs);
6. Substitute Specification (78 pgs);
7. Statement in Support of Substitute Specification (1 pg);
8. Check No. 13869 in the amount of \$1,960.00 to cover extension fee; and,
9. Computer Readable Form copy of the "Sequence Listing" (1 diskette);
10. Statement in Support of Computer Readable Form (1 pg.);
11. Paper Copy of "Sequence Listing" (10 pgs.)
12. Return postcard.

The Commissioner is hereby authorized to charge any fee that may be due, or to credit any overpayment, to Deposit Account No. 50-0311 (Reference No. 21402-042 (CURA-342)). A duplicate copy of this transmittal letter is enclosed.

Respectfully submitted,

Ivor R. Elrifi 42,767

Ivor R. Elrifi, Reg. No. 39,529

Attorney for Applicants

c/o MINTZ, LEVIN

One Financial Center

Boston, Massachusetts 02111

Tel: (617) 542-6000

Fax: (617) 542-2241

Dated: August 28, 2002

Express Mail Label No.: EV 80732US
Date of Deposit: August 28, 2002

10015253, 082802 #5
Attorney Docket No. 21402-042 (Cura-342)



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Rastelli, et al
SERIAL NUMBER: 10/016,253 EXAMINER: Not Yet Assigned
FILING DATE: December 10, 2001 ART UNIT: 1614
FOR: METHODS OF DETECTING AND TREATING TUBEROUS SCLEROSIS
COMPLEX ASSOCIATED DISORDERS

Commissioner for Patents and Trademarks
Washington, D.C. 20231


STATEMENT IN SUPPORT OF SUBSTITUTE SPECIFICATION

Pursuant to 37 CFR 1.125(b)(1), I hereby state that the content of the substitute specification and the specification filed on December 10, 2001 are the same. Applicants hereby submit this substitute specification in response to the Notice to File Missing Parts mailed on January 28, 2002, which specifically requested a substitute specification in compliance with 37 C.F.R. §1.52. The correction of the margins is the only amendment made to the specification at this time. Thus, this submission includes no new matter.

Applicants believe that no additional fees are required for the filing of the present submission. However, the Commissioner is hereby authorized to charge any additional fees that may be due, or credit any overpayment, to Deposit Account No. 50-0311, Ref. No. 21402-042 (Cura-342).

Respectfully submitted,

August 28, 2002


Ivor R. Elrifi, Reg. No. 39,529
Attorneys for Applicants
c/o MINTZ, LEVIN
One Financial Center
Boston, Massachusetts 02111
Tel: (617) 542-6000
Fax: (617) 542-2241

Express Mail Label No. EV058280732US
Date of Deposit: August 28, 2002

08-30-02
#6




UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
10/016,253	AUG 28 2002	Luca Rastelli	21402-042 (Cura 342)

CONFIRMATION NO. 4494

FORMALITIES LETTER



OC000000007378548

RECEIVED

FEB 01 2002

MINTZ, LEVIN, COHN, FERRIS,
GLOVSKY AND POPEO, P.C.
One Financial Center
Boston, MA 02111

MINTZ LEVIN, BOSTON
PATENT DOCKET DEPT.

Date Mailed: 01/28/2002

Done By
3/28/02

<input type="checkbox"/> Data Entry
<input checked="" type="checkbox"/> Docket Entry
<input type="checkbox"/> Docket Cross Off
<input type="checkbox"/> Previously Entered
<input type="checkbox"/> No Docketing Req
<input type="checkbox"/> ELITE

NOTICE TO FILE MISSING PARTS OF NONPROVISIONAL APPLICATION

FILED UNDER 37 CFR 1.53(b)

Filing Date Granted

An application number and filing date have been accorded to this application. The item(s) indicated below, however, are missing. Applicant is given **TWO MONTHS** from the date of this Notice within which to file all required items and pay any fees required below to avoid abandonment. Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a).

- The oath or declaration is unsigned.
- To avoid abandonment, a late filing fee or oath or declaration surcharge as set forth in 37 CFR 1.16(l) of \$130 for a non-small entity, must be submitted with the missing items identified in this letter.
- The balance due by applicant is \$ 130.

The application is informal since it does not comply with the regulations for the reason(s) indicated below.

The required item(s) identified below must be timely submitted to avoid abandonment:

- A substitute specification in compliance with 37 CFR 1.52 because:
 - Papers contain improper margins. Each sheet must have a left margin of at least 2.5 cm (1") and top, bottom and right margins of at least 2.0 cm (3/4")

This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant

09/03/2002 TBESHAKH 000000060 10016253

130.00 0P
01 FC:105

desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

*A copy of this notice **MUST** be returned with the reply.*



Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 1 - ATTORNEY/APPLICANT COPY